{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T10:36:54Z","timestamp":1763116614636,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CRUKD\/17\/008"],"award-info":[{"award-number":["CRUKD\/17\/008"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2996-6","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T13:41:51Z","timestamp":1541770911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["RIVA \u2013 a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"19","author":[{"given":"Sean H.","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim M.","family":"Linton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2900-3806","authenticated-orcid":false,"given":"Joke","family":"Dhondt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Caddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liz","family":"Rossiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karan","family":"Vadher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keira","family":"Fines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura E.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Stanton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter W. M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"2996_CR1","unstructured":"Cancer research UK, Non-Hodgkin lymphoma statistics. 2016 [cited 2016 March 2016]; Available from: http:\/\/wwwcancerresearchukorg\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/non-hodgkin-lymphoma ."},{"key":"2996_CR2","first-page":"439","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, et al. In: FT B, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth ed. Lyon: International Agency for Research on Cancer; 2008. p. 439.","edition":"Fourth"},{"issue":"4","key":"2996_CR3","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417\u201323.","journal-title":"Blood"},{"issue":"12","key":"2996_CR4","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040\u20135.","journal-title":"Blood"},{"issue":"11","key":"2996_CR5","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013\u201322.","journal-title":"Lancet Oncol"},{"key":"2996_CR6","doi-asserted-by":"crossref","unstructured":"Salles A, et al. Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy. Blood. 2013;122(21):509.","DOI":"10.1182\/blood.V122.21.509.509"},{"issue":"3","key":"2996_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00277-013-1900-4","volume":"93","author":"AJ Olszewski","year":"2014","unstructured":"Olszewski AJ, Ali S. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma. Ann Hematol. 2014;93(3):449\u201358.","journal-title":"Ann Hematol"},{"issue":"6","key":"2996_CR8","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/10428190902878471","volume":"50","author":"C Stolz","year":"2009","unstructured":"Stolz C, Schuler M. Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leuk Lymphoma. 2009;50(6):873\u201385.","journal-title":"Leuk Lymphoma"},{"issue":"27","key":"2996_CR9","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184\u201390.","journal-title":"J Clin Oncol"},{"issue":"16","key":"2996_CR10","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","volume":"44","author":"MJ Glennie","year":"2007","unstructured":"Glennie MJ, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16):3823\u201337.","journal-title":"Mol Immunol"},{"issue":"1","key":"2996_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3324\/haematol.2008.001628","volume":"95","author":"SH Lim","year":"2010","unstructured":"Lim SH, et al. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica. 2010;95(1):135\u201343.","journal-title":"Haematologica"},{"issue":"4","key":"2996_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes RA, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443\u20136.","journal-title":"Nat Med"},{"issue":"2","key":"2996_CR13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","volume":"174","author":"Q Gong","year":"2005","unstructured":"Gong Q, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174(2):817\u201326.","journal-title":"J Immunol"},{"issue":"25","key":"2996_CR14","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","volume":"115","author":"SA Beers","year":"2010","unstructured":"Beers SA, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115(25):5191\u2013201.","journal-title":"Blood"},{"issue":"7378","key":"2996_CR15","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480\u20139.","journal-title":"Nature"},{"issue":"14","key":"2996_CR16","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-11-3308","volume":"18","author":"LA Vitale","year":"2012","unstructured":"Vitale LA, et al. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res. 2012;18(14):3812\u201321.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2996_CR17","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.4049\/jimmunol.139.5.1589","volume":"139","author":"RA van Lier","year":"1987","unstructured":"van Lier RA, et al. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J Immunol. 1987;139(5):1589\u201396.","journal-title":"J Immunol"},{"issue":"4","key":"2996_CR18","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.4049\/jimmunol.149.4.1199","volume":"149","author":"K Sugita","year":"1992","unstructured":"Sugita K, et al. Participation of the CD27 antigen in the regulation of IL-2-activated human natural killer cells. J Immunol. 1992;149(4):1199\u2013203.","journal-title":"J Immunol"},{"issue":"12","key":"2996_CR19","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.4049\/jimmunol.172.12.7432","volume":"172","author":"Y Xiao","year":"2004","unstructured":"Xiao Y, et al. CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. J Immunol. 2004;172(12):7432\u201341.","journal-title":"J Immunol"},{"issue":"21","key":"2996_CR20","doi-asserted-by":"publisher","first-page":"13353","DOI":"10.1074\/jbc.273.21.13353","volume":"273","author":"H Akiba","year":"1998","unstructured":"Akiba H, et al. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase\/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem. 1998;273(21):13353\u20138.","journal-title":"J Biol Chem"},{"issue":"7","key":"2996_CR21","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1002\/(SICI)1521-4141(199807)28:07<2208::AID-IMMU2208>3.0.CO;2-L","volume":"28","author":"LA Gravestein","year":"1998","unstructured":"Gravestein LA, et al. The TNF receptor family member CD27 signals to Jun N-terminal kinase via Traf-2. Eur J Immunol. 1998;28(7):2208\u201316.","journal-title":"Eur J Immunol"},{"issue":"4","key":"2996_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.immuni.2004.08.009","volume":"21","author":"P Ramakrishnan","year":"2004","unstructured":"Ramakrishnan P, Wang W, Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity. 2004;21(4):477\u201389.","journal-title":"Immunity"},{"issue":"6","key":"2996_CR23","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/jid.2012.26","volume":"132","author":"ME Polak","year":"2012","unstructured":"Polak ME, et al. CD70-CD27 interaction augments CD8+ T-cell activation by human epidermal Langerhans cells. J Invest Dermatol. 2012;132(6):1636\u201344.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"2996_CR24","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.4049\/jimmunol.180.7.4615","volume":"180","author":"VY Taraban","year":"2008","unstructured":"Taraban VY, et al. Invariant NKT cells promote CD8+ cytotoxic T cell responses by inducing CD70 expression on dendritic cells. J Immunol. 2008;180(7):4615\u201320.","journal-title":"J Immunol"},{"issue":"11","key":"2996_CR25","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.4049\/jimmunol.173.11.6542","volume":"173","author":"VY Taraban","year":"2004","unstructured":"Taraban VY, Rowley TF, Al-Shamkhani A. Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J Immunol. 2004;173(11):6542\u20136.","journal-title":"J Immunol"},{"issue":"5","key":"2996_CR26","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.4049\/jimmunol.177.5.2969","volume":"177","author":"VY Taraban","year":"2006","unstructured":"Taraban VY, et al. Requirement for CD70 in CD4+ Th cell-dependent and innate receptor-mediated CD8+ T cell priming. J Immunol. 2006;177(5):2969\u201375.","journal-title":"J Immunol"},{"issue":"10","key":"2996_CR27","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.4049\/jimmunol.172.10.6039","volume":"172","author":"TF Rowley","year":"2004","unstructured":"Rowley TF, Al-Shamkhani A. Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo. J Immunol. 2004;172(10):6039\u201346.","journal-title":"J Immunol"},{"issue":"12","key":"2996_CR28","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1002\/eji.201343579","volume":"43","author":"VY Taraban","year":"2013","unstructured":"Taraban VY, et al. CD27 costimulation contributes substantially to the expansion of functional memory CD8(+) T cells after peptide immunization. Eur J Immunol. 2013;43(12):3314\u201323.","journal-title":"Eur J Immunol"},{"issue":"1","key":"2996_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.4049\/jimmunol.1301217","volume":"193","author":"JE Willoughby","year":"2014","unstructured":"Willoughby JE, et al. Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization. J Immunol. 2014;193(1):244\u201351.","journal-title":"J Immunol"},{"issue":"1","key":"2996_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4049\/jimmunol.1401644","volume":"194","author":"SL Buchan","year":"2015","unstructured":"Buchan SL, et al. OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence. J Immunol. 2015;194(1):125\u201333.","journal-title":"J Immunol"},{"issue":"8","key":"2996_CR31","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.4049\/jimmunol.1300409","volume":"191","author":"LZ He","year":"2013","unstructured":"He LZ, et al. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol. 2013;191(8):4174\u201383.","journal-title":"J Immunol"},{"issue":"18","key":"2996_CR32","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2016.70.1508","volume":"35","author":"HA Burris","year":"2017","unstructured":"Burris HA, et al. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. J Clin Oncol. 2017;35(18):2028\u201336.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2996_CR33","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1200\/jco.2014.32.15_suppl.3024","volume":"32","author":"SM Ansell","year":"2014","unstructured":"Ansell SM, et al. Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies. J Clin Oncol. 2014;32(15_suppl):3024.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2996_CR34","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ccell.2017.11.001","volume":"32","author":"AH Turaj","year":"2017","unstructured":"Turaj AH, et al. Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. Cancer Cell. 2017;32(6):777\u2013791 e6.","journal-title":"Cancer Cell"},{"issue":"27","key":"2996_CR35","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"21","key":"2996_CR36","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489\u201396.","journal-title":"Blood"},{"key":"2996_CR37","unstructured":"University Hospital Southampton NHS Foundation Trust. http:\/\/www.uhs.nhs.uk\/Research\/Research.aspx . Accessed 31 May 2018."},{"issue":"6","key":"2996_CR38","first-page":"506","volume":"38","author":"AW Chan","year":"2015","unstructured":"Chan AW, et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Rev Panam Salud Publica. 2015;38(6):506\u201314.","journal-title":"Rev Panam Salud Publica"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2996-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2996-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2996-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T22:46:45Z","timestamp":1694040405000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2996-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2996"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2996-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"27 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial received a favourable ethical opinion from South Central \u2013 Oxford A Ethics Committee (17\/SC\/0317) and has Health Research Authority approval (IRAS 223132). All participants will provide written informed consent before participating and are free to withdraw at any time.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SHL is co-inventor on a patent application filed (JDM84560P.GBA) and receives research funding from Celldex Therapeutics.AJD declares the following competing interests:All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"619"}}